ScreenerHero
DHRDanaher Corporation
NYSE · US · Healthcare · Diagnostics & Research · danaher.com
219.94USD+1.87%Mkt Cap: 151.78B $P/E: 38.56

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, L…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
LONN
Lonza Group Ltd
$46.70BUSDP/E 37.9
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8

Key Statistics

Company
Market Cap151.78B $
Enterprise Value175.30B $
Revenue (TTM)25.11B $
Gross Profit14.52B $
Net Income (TTM)3.61B $
Revenue/Share35.47 USD
Last Price219.94 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees58.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)38.56
P/E (Forward)23.22
PEG1.38
EV/EBITDA21.84
EV/Revenue6.98
P/S6.05
P/B2.89
EPS (TTM)5.72
EPS (Forward)9.30
52W Range
160.9372% of range242.80
52W High242.80 USD
52W Low160.93 USD
Profitability
Gross Margin59.11%
Oper. Margin19.78%
EBITDA Margin31.97%
Profit Margin14.71%
ROE6.88%
ROA4.33%
Growth
Revenue Growth5.50%
Earnings Growth59.70%
Cash Flow & Leverage
Operating CF6.42B $
CapEx (TTM)1.16B $
FCF Margin17.23%
FCF Yield2.85%
Net Debt23.51B $
Net Debt/EBITDA2.93
Balance Sheet
Debt/Equity0.37
Current Ratio1.65
Quick Ratio1.15
Book Value/Sh74.81 USD
Cash/Share6.185 USD
Dividends
Fwd Div Rate1.600 USD
Trail. Div Rate1.440 USD
Div. Yield0.76%
5Y Avg Yield0.44%
Payout Ratio25.67%
Ex-Div DateJun 26, 2026
Pay DateJul 31, 2026
Splits
Last Split1128:1000
Split DateOct 2, 2023
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)227.96 USD
Upside (mean)+3.6%
Target Range195.00 USD – 310.00 USD
$195.00+3.6% to mean$310.00
# Analysts23
Ownership
Shares Out.702.99M
Float625.83M
Insiders10.96%
Institutions84.51%
Short Interest
Short Ratio1.9d
Short % Float1.92%
Short % Out.1.72%
Shares Short12.07M
Short (prev mo.)10.86M
Technical
SMA 50194.73 (+12.9%)
SMA 200202.95 (+8.4%)
Beta0.80
S&P 52W Chg18.16%
Avg Vol (30d)4.76M
Avg Vol (10d)3.27M
Technical Indicators
RSI (14)67.4
MACD4.5344
MACD Signal3.5765
MACD Hist.+0.9580
BB Upper214.25 USD
BB Middle201.16 USD
BB Lower188.06 USD
BB Width13.02%
ATR (14)6.797 USD
Vol Ratio (20d)1.14x